The company ended 2017 with $10 million in cash and cash equivalents, and raised $40 million in a public offering in January.
The company will use a portion of the credit facility to fund its announced acquisition of Integrated DNA Technologies.
The firm also increased the size of its Series G preferred shares offering and will use the funds to develop tests for guiding the use of cancer immunotherapy.
Perceptive Credit Holdings has agreed to provide the company with the loan, which CareDx said it will use to repay outstanding debt.
The loan can be funded at Invitae's option during the second quarter of 2018 and will provide flexibility as the firm grows its genome network.
The firm said it expects to finance the construction of a clinical lab and related facilities, as well as additional development of a 46-acre campus.
The company immediately borrowed $255 million to pay part of the $680 million price tag for Alere's MeterPro cardiovascular and toxicology business and its BNP assay business.
Brooks also said it has signed a seven-year, $200 million senior term loan agreement with a group of institutional investors.
The firm said that it expects to use the proceeds of the senior notes offering to contribute to retirement of remaining convertible notes.
The firm said it may use the loans to finance its $1.3 billion acquisition of Euroimmun Medical Laboratory Diagnostics.
Mice in New York harbor both antibiotic-resistant bacteria and novel viruses, according to a new analysis of their fecal microbiomes.
Human Heredity and Health in Africa Initiative has issued guidelines for genomic research in the region, according to Nature News.
The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.
In Genome Biology this week: approach to analyze alternative polyadenylation, algorithm to predict transcriptomic structural variations, and more.